Medivation, Inc. (NASDAQ: MDVN) is a large market cap stock with a market cap of 10272.73. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 43.7, a forward P/E of 28.46 and EPS of 1.43. At a stock price of 63.98 (2.38%) it has a dividend yield of *TBA.
EPS growth for the last five years have been 50.90%, more recently this last year it has grown by -11.10%. The next year growth is going to be about 70.50% and more long-term 35.15% after five years. EPS growth quarter over quarter is 243.60%. Sales growth for the past five years have been 72.10% and sales growth quarter over quarter is 41.30%.
For performance, Medivation, Inc. the past week has seen a gain of -0.08%. For the last month performance for Medivation, Inc. is 8.13%. While the last quarter is 11.25% and half year, 88.85%. Finally for the year, performance is 30.54%.
The 52-week high for Medivation, Inc., is at 0.99%, and for the 52-week low it comes to a value of 142.26%. The 20-day simple moving average is 5.31% and 35.45% for the 200-day simple moving average.
Volatility for the week is at 1.60%, and for the month it is 1.81%. Medivation, Inc., has a target price of 64.82.
In terms of debt, long term debt/equity is 0, and for total debt/equity Medivation, Inc. has 0. The gross margin is *TBA, while operating margin is 40.20%, the profit margin is 25.40%. The current ratio is 4.2 and the quick ratio is 4.2.
Insider ownership is at 1.20%, with instituitional ownership at 93.00%. Medivation, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 164.39. The shares float is 162.47, with the float short at 1.97%, with short ratio coming to 1.26.
In terms of returns, the return on assets see Medivation, Inc., get 21.50%, with its returns on investment at 27.10%. Return on equity is 34.00%. So will the investors see the target price of 64.82, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.